Ara
Toplam kayıt 14, listelenen: 11-14
Imaging and technologies for prostate cancer. Where are we now-where do we go?
(Springer, 2021)
We have been witnessing rapid advances in the diagnosis and treatment of prostate cancer. While some approaches have matured, others are still in their infancy. We have learned that Active Surveillance is safe in patients ...
A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low-intermediate risk prostate cancer. Reply.
(Wolters Kluwer Health, 2023)
To the Editor: We appreciate this opportunity toaddress the concerns in the comment by Jin et al on ourarticle,1evaluating the adverse events and quality of lifeafter irreversible electroporation (IRE) for the ablationof ...
Focal therapy for prostate cancer: Evolutionary parallels to breast cancer treatment. Letter.
(Wolters Kluwer Health, 2023)
To the Editor:We read with great interest the recentmanuscript by Labbate et al reviewing the develop-ment of focal therapy in breast and prostate cancer(PCa).1Breast focal therapy (bFT) represents a suc-cessful model for ...
Effect of focal vs extended irreversible electroporation for the ablation of localized low- or intermediate-risk prostate cancer on early oncological control: A randomized clinical trial
(American Medical Association, 2023)
Importance: Focal ablative irreversible electroporation (IRE) is a therapy that treats only the area of the tumor with the aim of achieving oncological control while reducing treatment-related functional detriment. Objective: ...